Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 65 | 2 | 59 | −4 |
| Shares | 66.2M | 351.8K | 60.8M | −5.04M (−7.7%) |
| Value | $48.3M | $256.9K | $19.5M | −$28.5M (−59.4%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 65,592 | $21.0K | 0.00% |
| Tri Locum Partners LP | 38,847 | $12.0K | 0.01% |
| Merit Financial Group, LLC | 32,000 | $10.3K | 0.00% |
| Lee Danner & Bass Inc | 27,763 | $9.00K | 0.00% |
| Renaissance Technologies LLC | 28,200 | $9.00K | 0.00% |
| Two Sigma Securities, LLC | 14,615 | $4.69K | 0.00% |
| FMR LLC | 10 | $3 | 0.00% |
| CoreCap Advisors, LLC | 5 | $2 | 0.00% |
| Simplex Trading, LLC | 29 | $0 | 0.00% |
Sold out (13)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| OrbiMed Advisors LLC | 1,882,768 | $1.37M |
| Fort Sheridan Advisors LLC | 135,000 | $99.0K |
| Caliber Wealth Management, LLC | 75,120 | $55.0K |
| Qube Research & Technologies Ltd | 54,398 | $40.0K |
| Balyasny Asset Management LLC | 52,887 | $39.0K |
| Cubist Systematic Strategies, LLC | 40,718 | $30.0K |
| D. E. Shaw & Co., Inc. | 38,291 | $28.0K |
| Price T Rowe Associates Inc | 36,600 | $27.0K |
| Citadel Advisors LLC | 27,454 | $20.0K |
| National Asset Management, Inc. | 17,890 | $14.0K |
| Y-Intercept (Hong Kong) Ltd | 11,469 | $8.37K |
| Virtu Financial LLC | 10,558 | $8.00K |
| China Universal Asset Management Co., Ltd. | 1,111 | $1.00K |
Not filed for Q4 2022 yet (2)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ACT Capital Management, LLC | 330,000 | $241.0K |
| American Portfolios Advisors | 21,830 | $15.9K |